Suppr超能文献

多柔比星耐药人白血病细胞系中拓扑异构酶I活性和重组激活基因表达的改变

Altered topoisomerase I activity and recombination activating gene expression in a human leukemia cell line resistant to doxorubicin.

作者信息

Riou J F, Grondard L, Petitgenet O, Abitbol M, Lavelle F

机构信息

Département Biologie, Centre de Recherche de Vitry-Alfortville, Vitry-sur-Seine, France.

出版信息

Biochem Pharmacol. 1993 Sep 1;46(5):851-61. doi: 10.1016/0006-2952(93)90494-h.

Abstract

We examined the expression of the genes encoding topoisomerases I and II and those associated with V(D)J [variable(diversity)joining] recombination in two human T-cell acute lymphoblastic leukemia (T.ALL) cell lines, CEM and CEM/DOX. In CEM/DOX cells, which are resistant to doxorubicin, the topoisomerase I gene was found to be 4-fold overexpressed and nuclear topoisomerase I relaxation activity was 2-fold greater in CEM/DOX than in CEM cells. Furthermore, the cleavable complex reaction induced by camptothecin, a specific topoisomerase I inhibitor, was found to be 2.5-increased in the presence of topoisomerase I extracted from CEM/DOX, in comparison to that in CEM cells. Conversely, the topoisomerase II mRNA levels, nuclear decatenation activities and (mAMSA) 4'(9-acridinylamino)methanesulfon-m-anisidide-induced cleavable complex formation in CEM/DOX were similar to those of the doxorubicin-sensitive cells. The results indicate that topoisomerase I activity is elevated in CEM/DOX cells. Nevertheless, CEM/DOX cells were 11-fold more resistant to camptothecin than were CEM cells, and cross-resistance to camptothecin was not reversed by verapamil. Furthermore, using an intact cell assay for DNA-protein complexes, we found that camptothecin-stimulated cleavable complexes formed in CEM/DOX cells were increased in correlation with the elevated topoisomerase I activity. These results suggest that camptothecin resistance in CEM/DOX cells is due to different mechanism(s) than topoisomerase- or P-glycoprotein-associated multidrug resistance. The recombination activating gene, RAG1, which is one of the components of the site-specific V(D)J recombination complex, was 20-fold overexpressed in CEM/DOX cells. In contrast, RAG2 and T160 gene transcripts, other components of the V(D)J complex, were at best poorly detected in both sensitive and resistant cells. No specific V(D)J recombinase activity was found in CEM or CEM/DOX cells when the pJH201 transfection assay was used. The results indicate that CEM/DOX cells failed to generate V(D)J recombination although RAG1 gene is overexpressed. The mechanism of the RAG1 gene activation was not gene amplification, and no rearrangement was detected in the RAG1 gene locus. RAG1 presents homology with the yeast gene HPR1, itself homologous to yeast topoisomerase I and responsible for the control of recombination in somatic cells. Since DNA topoisomerases are themselves involved in the control of DNA topology, recombination and DNA repair, the possible coactivation of RAG1 and topoisomerase I genes in CEM/DOX cells is discussed.

摘要

我们检测了编码拓扑异构酶I和II以及与V(D)J[可变(多样)连接]重组相关基因在两种人T细胞急性淋巴细胞白血病(T-ALL)细胞系CEM和CEM/DOX中的表达。在对阿霉素耐药的CEM/DOX细胞中,发现拓扑异构酶I基因过表达4倍,且CEM/DOX细胞核拓扑异构酶I松弛活性比CEM细胞高2倍。此外,与CEM细胞相比,喜树碱(一种特异性拓扑异构酶I抑制剂)诱导的可裂解复合物反应在存在从CEM/DOX中提取的拓扑异构酶I时增加了2.5倍。相反,CEM/DOX中的拓扑异构酶II mRNA水平、核解连环活性以及(4′-(9-吖啶基氨基)甲磺酰基间茴香胺)mAMSA诱导的可裂解复合物形成与阿霉素敏感细胞相似。结果表明CEM/DOX细胞中拓扑异构酶I活性升高。然而,CEM/DOX细胞对喜树碱的耐药性比CEM细胞高11倍,且维拉帕米不能逆转对喜树碱的交叉耐药性。此外,使用完整细胞检测DNA-蛋白质复合物,我们发现CEM/DOX细胞中喜树碱刺激形成的可裂解复合物与升高的拓扑异构酶I活性相关增加。这些结果表明,CEM/DOX细胞对喜树碱的耐药性是由不同于拓扑异构酶或P-糖蛋白相关多药耐药性的机制引起的。重组激活基因RAG1是位点特异性V(D)J重组复合物的组成部分之一,在CEM/DOX细胞中过表达20倍。相比之下,V(D)J复合物的其他组成部分RAG2和T160基因转录本在敏感和耐药细胞中最多只能勉强检测到。当使用pJH201转染检测时,在CEM或CEM/DOX细胞中未发现特异性V(D)J重组酶活性。结果表明尽管RAG1基因过表达,CEM/DOX细胞仍未能产生V(D)J重组。RAG1基因激活的机制不是基因扩增,并且在RAG1基因位点未检测到重排。RAG1与酵母基因HPR1具有同源性,HPR1本身与酵母拓扑异构酶I同源,负责体细胞中重组的控制。由于DNA拓扑异构酶本身参与DNA拓扑结构、重组和DNA修复的控制,因此讨论了CEM/DOX细胞中RAG1和拓扑异构酶I基因可能的共激活。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验